Casdin Capital significantly increased its investment in Sarepta Therapeutics, boosting its holdings by over 287% to 1.82 million shares. This quarterly disclosure, filed on November 16, 2026, reflects the firm's position as of September 30, 2026. The reported value of Casdin's stake grew from $8.45 million to $33.16 million during the third quarter.

The trade occurred before Sarepta announced third-quarter earnings on November 5th that beat analyst estimates, leading the company to raise its full-year revenue guidance. Despite this, the stock has recently faced pressure, hitting a 52-week low on November 17 amid concerns over future product growth. The company expects data from other pipeline candidates by the end of 2026.